Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma

Lucia Loni, Filippo De Braud, Pier Luigi Zinzani, Romano Danesi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The variability of tumor responses to chemotherapeutic agents is a topic of major interest in current cancer research. Advances in the knowledge of dysregulation of key molecular pathways in cancer cells have enabled techniques to be developed that can profile tumor cells for their genetic background, allowing selection of anticancer agents on an individual basis. The next generation of anticancer treatments might therefore be tailored according to the molecular alterations identified in tumor cells of individual patients. However, before these alterations can be exploited from a therapeutic point of view, it is necessary to understand how such alterations influence the cellular pathways that control sensitivity to chemotherapeutic agents. Pharmacogenetics and pharmacoproteomics, novel disciplines that investigate the relationship between gene and protein expression in tumor cells and the response to anticancer agents, will be instrumental in developing optimal chemotherapeutic regimens for patients with non-Hodgkin's lymphoma.

Original languageEnglish
JournalLeukemia and Lymphoma
Volume44
Issue numberSUPPL. 3
DOIs
Publication statusPublished - 2003

Fingerprint

Pharmacogenetics
Proteomics
Non-Hodgkin's Lymphoma
Pharmaceutical Preparations
Neoplasms
Antineoplastic Agents
Gene Expression
Therapeutics
Research
Proteins

Keywords

  • Chemotherapy
  • Non-Hodgkin's lymphoma
  • Pharmacogenetics
  • Pharmacoproteomics

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma. / Loni, Lucia; De Braud, Filippo; Zinzani, Pier Luigi; Danesi, Romano.

In: Leukemia and Lymphoma, Vol. 44, No. SUPPL. 3, 2003.

Research output: Contribution to journalArticle

Loni, Lucia ; De Braud, Filippo ; Zinzani, Pier Luigi ; Danesi, Romano. / Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma. In: Leukemia and Lymphoma. 2003 ; Vol. 44, No. SUPPL. 3.
@article{50991c37fd784a23bedba8ccaadfcd95,
title = "Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma",
abstract = "The variability of tumor responses to chemotherapeutic agents is a topic of major interest in current cancer research. Advances in the knowledge of dysregulation of key molecular pathways in cancer cells have enabled techniques to be developed that can profile tumor cells for their genetic background, allowing selection of anticancer agents on an individual basis. The next generation of anticancer treatments might therefore be tailored according to the molecular alterations identified in tumor cells of individual patients. However, before these alterations can be exploited from a therapeutic point of view, it is necessary to understand how such alterations influence the cellular pathways that control sensitivity to chemotherapeutic agents. Pharmacogenetics and pharmacoproteomics, novel disciplines that investigate the relationship between gene and protein expression in tumor cells and the response to anticancer agents, will be instrumental in developing optimal chemotherapeutic regimens for patients with non-Hodgkin's lymphoma.",
keywords = "Chemotherapy, Non-Hodgkin's lymphoma, Pharmacogenetics, Pharmacoproteomics",
author = "Lucia Loni and {De Braud}, Filippo and Zinzani, {Pier Luigi} and Romano Danesi",
year = "2003",
doi = "10.1080/10428190310001623676",
language = "English",
volume = "44",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma

AU - Loni, Lucia

AU - De Braud, Filippo

AU - Zinzani, Pier Luigi

AU - Danesi, Romano

PY - 2003

Y1 - 2003

N2 - The variability of tumor responses to chemotherapeutic agents is a topic of major interest in current cancer research. Advances in the knowledge of dysregulation of key molecular pathways in cancer cells have enabled techniques to be developed that can profile tumor cells for their genetic background, allowing selection of anticancer agents on an individual basis. The next generation of anticancer treatments might therefore be tailored according to the molecular alterations identified in tumor cells of individual patients. However, before these alterations can be exploited from a therapeutic point of view, it is necessary to understand how such alterations influence the cellular pathways that control sensitivity to chemotherapeutic agents. Pharmacogenetics and pharmacoproteomics, novel disciplines that investigate the relationship between gene and protein expression in tumor cells and the response to anticancer agents, will be instrumental in developing optimal chemotherapeutic regimens for patients with non-Hodgkin's lymphoma.

AB - The variability of tumor responses to chemotherapeutic agents is a topic of major interest in current cancer research. Advances in the knowledge of dysregulation of key molecular pathways in cancer cells have enabled techniques to be developed that can profile tumor cells for their genetic background, allowing selection of anticancer agents on an individual basis. The next generation of anticancer treatments might therefore be tailored according to the molecular alterations identified in tumor cells of individual patients. However, before these alterations can be exploited from a therapeutic point of view, it is necessary to understand how such alterations influence the cellular pathways that control sensitivity to chemotherapeutic agents. Pharmacogenetics and pharmacoproteomics, novel disciplines that investigate the relationship between gene and protein expression in tumor cells and the response to anticancer agents, will be instrumental in developing optimal chemotherapeutic regimens for patients with non-Hodgkin's lymphoma.

KW - Chemotherapy

KW - Non-Hodgkin's lymphoma

KW - Pharmacogenetics

KW - Pharmacoproteomics

UR - http://www.scopus.com/inward/record.url?scp=1042303635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1042303635&partnerID=8YFLogxK

U2 - 10.1080/10428190310001623676

DO - 10.1080/10428190310001623676

M3 - Article

C2 - 15202534

AN - SCOPUS:1042303635

VL - 44

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - SUPPL. 3

ER -